A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

12.2K views

⸱

DOI:

10.3791/56075

⸱

July 26th, 2017

 ,  ,  ,  , 

In This Article

Summary

Toll-like receptor (TLR) signaling plays an important role in the pathophysiology of many human inflammatory diseases, and regulating TLR responses by bioactive nanoparticles is anticipated to be beneficial in many inflammatory conditions. THP-1 cell-based reporter cells provide a versatile and robust screening platform for identifying novel inhibitors of TLR signaling.

Abstract

Pharmacological regulation of Toll-like receptor (TLR) responses holds great promise in the treatment of many inflammatory diseases. However, there have been limited compounds available so far to attenuate TLR signaling and there have been no clinically approved TLR inhibitors (except the anti-malarial drug hydroxychloroquine) in clinical use. In light of rapid advances in nanotechnology, manipulation of immune responsiveness using nano-devices may provide a new strategy to treat these diseases. Herein, we present a high throughput screening method for quickly identifying novel bioactive nanoparticles that inhibit TLR signaling in phagocytic immune cells. This screening platform is built on THP-1 cell-based reporter cells with colorimetric and luciferase assays. The reporter cells are engineered from the human THP-1 monocytic cell line by stable integration of two inducible reporter constructs. One expresses a secreted embryonic alkaline phosphatase (SEAP) gene under the control of a promoter inducible by the transcription factors NF-κB and AP-1, and the other expresses a secreted luciferase reporter gene under the control of promoters inducible by interferon regulatory factors (IRFs).Upon TLR stimulation, the reporter cells activate transcription factors and subsequently produce SEAP and/or luciferase, which can be detected using their corresponding substrate reagents. Using a library of peptide-gold nanoparticle (GNP) hybrids established in our previous studies as an example, we identified one peptide-GNP hybrid that could effectively inhibit the two arms of TLR4 signaling cascade triggered by its prototypical ligand, lipopolysaccharide (LPS). The findings were validated by standard biochemical techniques including immunoblotting. Further analysis established that this lead hybrid had a broad inhibitory spectrum, acting on multiple TLR pathways, including TLR2, 3, 4, and 5. This experimental approach allows a rapid assessment of whether a nanoparticle (or other therapeutic compounds) can modulate specific TLR signaling in phagocytic immune cells.

Introduction

Toll-like receptors (TLRs) are one of the key elements in the innate immune system contributing to the first line of defense against infections. TLRs are responsible for sensing invading pathogens by recognizing a repertoire of pathogen-associated molecular patterns (or PAMPs) and mounting defense reactions through a cascade of signal transduction1,2. There are 10 human TLRs identified; except TLR10 for which the ligand(s) remain unclear, each TLR can recognized a distinct, conserved group of PAMPs. For example, TLR2 and TLR4, primarily located on the cell surface, can detect lipoproteins and glycolipids from ....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Preparation of Cell Culture Media and Reagents

  1. Prepare the complete cell culture medium R10 by adding the supplements of 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1 mM sodium pyruvate into the RPMI-1640 medium.
    1. Prepare the selection culture medium R10-Z by adding the antibiotics Zeocin (200 μg/mL) to R10 for maintaining the expression of SEAP under the control of NF-κB/AP-1 activation. To select for cells expressing both SEAP and luciferase reporter genes, add both Zeocin (100 μg/mL) and blasticidin (10 μg/mL) to R10 (as R10-ZB).
  2. Prepare the SEAP substrate solution....

Access restricted. Please log in or start a trial to view this content.

Results

The overall experimental approach is illustrated in Figure 1. The two THP-1 reporter cell lines, THP-1-XBlue and THP-1-Dual, are used to fast screen the TLR responses by probing the activation of NF-κB/AP-1 and IRFs, respectively. The activation of NF-κB/AP-1 can be detected by the SEAP colorimetric assay, whereas IRF activation is monitored by luciferase luminescence. The monocytic THP-1 cells can be easily derived into macrophages to screen the nanodevices .......

Access restricted. Please log in or start a trial to view this content.

Discussion

Since TLRs are involved in the pathogenesis of many inflammatory diseases, they have emerged as therapeutic targets for the modulation of immune responses and inflammatory conditions. However, the clinical development of therapeutics to inhibit TLR signaling pathways has had limited success to date. The antimalarial drug hydroxychloroquine which inhibits TLR7 and TLR9 is in clinical use35,36. Similarly, only a limited number of compounds have progressed to c.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors would like to acknowledge the support from the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (H.Y.), the starting fund from Shanghai First People's Hospital (H.Y.), Gaofeng Clinical Medicine Grant support from Shanghai Jiaotong University School of Medicine (H.Y.), and the funding from the Crohn's and Colitis Foundation of Canada (CCFC) (S.E.T. and H.Y.).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
THP-1-XBlue reporter cellInvivoGenthpx-spkeep cell culture passage under 20
THP-1-Dual repoter cellInvivoGenthpd-nfiskeep cell culture passage under 20
RPMI-1640 (no L-glutamine)GE Health CareSH30096.02Warm up to 37 °C before use; add supplements to make a complete medium R10
Fetal bovine serum (qualified)Thermo Fisher Scientific12484028Heat inactivated; 10% in RPMI-1640
L-glutamineThermo Fisher ScientificSH30034.022 mM in the complete medium R10
Sodium pyruvateThermo Fisher Scientific11360-0701 mM in the complete medium R10
Dulbecco's phosphate buffered saline, 1X, without calcium, magnesiumGE Health CareSH30028.02Use for cell washing and reagent preparation
QUANTI-BlueInvivoGenrep-qb1SEAP substrate
QUANTI-LucInvivoGenrep-qlc2Luciferase substrate
ZeocinInvivoGenant-zn-1Selection antibiotics for reporter cells
BlasticidinInvivoGenanti-bl-1Selection antibiotics for reporter cells
Dimethyl sulfoxide (DMSO) for molecular biologySigmal-AldrichD8418-100MLUse for reagent preparation
Phorbol 12-myristate 13-acetate (PMA) for molecular biologySigmal-AldrichP1585-1MGUse for cell differentiation
Lipopolysaccharide (LPS) from E. coli K12InvivoGentlrl-eklpsTLR4 ligand
Pam3CSK4InvivoGentlrl-pmsTLR2/1 ligand
Poly (I:C) HMWInvivoGentlrl-picTLR3 ligand
Flagellin from S. Typhimurium (FLA-ST), ultrapureInvivoGentlrl-epstflaTLR5 ligand
SpectraMax Plus 384 microplate readerMolecular DevicesN/ARead colorimetric assay
Infinite M200 Pro multimode microplate reader with injectorsTecanN/ARead luminiscience
Microfuge 22R centrifugeBeckman CoulterN/ATemperature controlled micro-centrifugator (up to 18,000 g)
Allegra X-15R centrifugeBeckman CoulterN/ATemperature controlled general purpose centrifugator (for cell culture use)
Costar assay plate, 96-well white with clear flat bottom, tissue culure treatedCorning Costar3903Used for luminiscence assay

References

  1. Akira, S., Takeda, K. Toll-like receptor signalling. Nat Rev Immunol. 4 (7), 499-511 (2004).
  2. Beutler, B. A. TLRs and innate immunity. Blood. 113 (7), 1399-1407 (2009).
  3. Gay, N. J., Symmons, M. F., Gangloff, M., Bryant, C. E.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Nanoparticle ScreeningTHP-1 Reporter CellsSEAP Luciferase AssayPeptide-Gold Nanoparticle HybridNF-kappaB AP1 ActivationIRF Luciferase AssayImmunoblotting ValidationInflammatory Disease Therapy